{"id":7364,"date":"2026-06-20T10:29:59","date_gmt":"2026-06-20T16:29:59","guid":{"rendered":"https:\/\/allphasepharma.com\/dir\/?p=7364"},"modified":"2026-06-20T10:34:31","modified_gmt":"2026-06-20T16:34:31","slug":"antibiotic-development-in-pharma-is-dead-for-now","status":"publish","type":"post","link":"https:\/\/allphasepharma.com\/dir\/2026\/06\/20\/7364\/antibiotic-development-in-pharma-is-dead-for-now\/","title":{"rendered":"ANTIBIOTIC DEVELOPMENT IN PHARMA IS DEAD \u2013 FOR NOW"},"content":{"rendered":"\n<figure class=\"wp-block-image alignfull size-large\"><a href=\"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/06\/FQ-Slider.jpg?ssl=1\"><img data-recalc-dims=\"1\" loading=\"lazy\" decoding=\"async\" width=\"530\" height=\"87\" src=\"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/06\/FQ-Slider.jpg?resize=530%2C87&#038;ssl=1\" alt=\"\" class=\"wp-image-7367\" srcset=\"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/06\/FQ-Slider.jpg?resize=1024%2C169&amp;ssl=1 1024w, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/06\/FQ-Slider.jpg?resize=300%2C50&amp;ssl=1 300w, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/06\/FQ-Slider.jpg?resize=768%2C127&amp;ssl=1 768w, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/06\/FQ-Slider.jpg?w=1090&amp;ssl=1 1090w\" sizes=\"auto, (max-width: 530px) 100vw, 530px\" \/><\/a><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">This is a somewhat nostalgic retro blog.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">I was leafing through a book by Vince Andriole called \u2018The Quinolones\u2019.<a href=\"#_ftn1\" id=\"_ftnref1\">[1]<\/a>&nbsp; First released in 1988, its third edition is from 2000.&nbsp; It provided in-depth coverage of quinolone chemistry, PK, microbiology, efficacy and safety.&nbsp; It was a great review of the large and growing field of gyrase\/topoisomerase inhibitors, with chapters written by the doyens of the day.&nbsp; From today\u2019s perspective, however, what we find most striking is the immense number of candidate drugs in development.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In presentations and slides Andriole reviewed more than 40 compounds at various stages of development.&nbsp; Of course, we still have ofloxacin\/levofloxacin, ciprofloxacin and moxifloxacin on the formulary.&nbsp; These, drugs from JNJ and Bayer, became blockbusters at a time when blockbusters were still rare.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">All but forgotten is the effort that went into \u2013 well, all the others!&nbsp; Below an admittedly incomplete list that is meant to bring back those exciting times, highlighting some key events and insights:<\/p>\n\n\n\n<figure class=\"wp-block-image alignfull size-full\"><a href=\"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/06\/image-3.png?ssl=1\"><img data-recalc-dims=\"1\" loading=\"lazy\" decoding=\"async\" width=\"530\" height=\"694\" src=\"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/06\/image-3.png?resize=530%2C694&#038;ssl=1\" alt=\"\" class=\"wp-image-7389\" srcset=\"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/06\/image-3.png?w=755&amp;ssl=1 755w, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/06\/image-3.png?resize=229%2C300&amp;ssl=1 229w\" sizes=\"auto, (max-width: 530px) 100vw, 530px\" \/><\/a><\/figure>\n\n\n\n<figure class=\"wp-block-image alignfull size-full\"><a href=\"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/06\/image-4.png?ssl=1\"><img data-recalc-dims=\"1\" loading=\"lazy\" decoding=\"async\" width=\"530\" height=\"256\" src=\"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/06\/image-4.png?resize=530%2C256&#038;ssl=1\" alt=\"\" class=\"wp-image-7390\" srcset=\"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/06\/image-4.png?w=756&amp;ssl=1 756w, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/06\/image-4.png?resize=300%2C145&amp;ssl=1 300w\" sizes=\"auto, (max-width: 530px) 100vw, 530px\" \/><\/a><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Over time, the FQ-related class AEs became clearer; they were mainly related to<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>GI and hepatic side effects<\/li>\n\n\n\n<li>Inactivation by divalent ions with PO dosing &nbsp;<\/li>\n\n\n\n<li>QT-prolongation<\/li>\n\n\n\n<li>Phototoxicity<\/li>\n\n\n\n<li>Chondrotoxicity and tendon rupture<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Many quinolones died because of the toxicities listed above.&nbsp; While QT prolongation was avoidable, other toxicities were not.&nbsp; Efficacy was always a given but safety issues often turned up only late in development.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">We are still not sure why temafloxacin was associated with HUS.&nbsp; Young patients with trivial infections but who were otherwise healthy died if the early symptoms were not recognized.&nbsp; This was not a class effect, never seen in any other FQ to the best of our knowledge.&nbsp; However, it served as a wake-up call that even if a class of drugs is well understood, every new member warrants individual scrutiny and careful monitoring.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">These toxicities represented a mine field; eventually we had an entire cemetery of FQs somewhere out there in pharma land.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Nonetheless, every Big Pharma had at least one FQ antibiotic in development.&nbsp; It was an attractive field for industry in those days and \u2013 despite set-backs and short duration therapy \u2013 a commercial success story.&nbsp; Antibacterial research benefitted from the fact that efficacy was predictable, PK was testable, and the only unknown was the AE profile.&nbsp; Still, FQs and antibacterial R&amp;D were a safer bet for approval than drugs in most other therapeutic areas.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">So why was antibiotic development considered lucrative then but no longer today?<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The short answer is that pricing for antibiotics remained behind compared to the steep rise in prices for cancer and immunology medicines.&nbsp; This gap became wider over time, it accelerated with the advent of costly therapies for rare disease agents, monoclonal antibodies, and medicines for chronic diseases in general.&nbsp; On the ID side, only HCV therapies and some HIV drugs commanded similarly high prices.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Of course, there is still an attractive niche in ID for HIV and HBV antivirals and for certain vaccines.&nbsp; However, it will probably take a Black Death-like epidemic to revive interest in antibacterials, before Big Pharma sees opportunities and gets seriously involved again.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Don\u2019t blame pharma companies for this state of affairs; they are doing exactly what\u2019s good for them and best for shareholders.&nbsp; Their mandate is to maximize profits first and foremost. There is no law that demands operating altruistically.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Regulators shape the market which ultimately determines which therapeutic areas are in demand.&nbsp; Companies are smart enough to find areas of lucrative engagement for their risky investments.&nbsp; The cost of developing a novel agent is certainly over 1 billion dollars nowadays, something often ignored by those who only look at manufacturing costs for any given product.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">A recent Nature article provides some insights into development costs and revenue streams for drugs approved between 2011 \u2013 2020.<a href=\"#_ftn2\">[2]<\/a>&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The authors explain why blockbusters are needed to compensate for \u2018duds\u2019, the many drugs that fail to make it to the market.&nbsp; They identified a total of 36 blockbuster drugs overall, 11 in oncology and 8 in ID.&nbsp; All the ID blockbuster drugs are HCV, HIV, or Covid antivirals (see Table), no antibacterial or antifungal made the list.<\/p>\n\n\n\n<figure class=\"wp-block-image alignfull size-full\"><a href=\"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/06\/image-2.png?ssl=1\"><img data-recalc-dims=\"1\" loading=\"lazy\" decoding=\"async\" width=\"530\" height=\"214\" src=\"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/06\/image-2.png?resize=530%2C214&#038;ssl=1\" alt=\"\" class=\"wp-image-7370\" srcset=\"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/06\/image-2.png?w=975&amp;ssl=1 975w, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/06\/image-2.png?resize=300%2C121&amp;ssl=1 300w, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/06\/image-2.png?resize=768%2C310&amp;ssl=1 768w\" sizes=\"auto, (max-width: 530px) 100vw, 530px\" \/><\/a><figcaption class=\"wp-element-caption\">Table 1: ID Blockbusters 2011-2020. Modified from Ref. <a href=\"#_ftn2\">[2]<\/a>&nbsp;<\/figcaption><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Not surprisingly, the main breakthrough occurred in the field of HCV therapeutics; these new agents truly revolutionized therapy in the past decade.&nbsp; Pomalyst should not be on this list; it is not an antibiotic but an immunology drug.&nbsp; Remdesivir flamed out early and is now almost obsolete. We reviewed the remdesivir story in a blog earlier this year [<a href=\"https:\/\/allphasepharma.com\/dir\/2025\/11\/27\/5814\/obeldesivir-fails-in-yet-another-study\/\" data-type=\"post\" data-id=\"5814\">Obeldesivir<\/a>].<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p class=\"alignwide has-blue-color has-text-color has-link-color wp-elements-0e89b709ed57a315b9136d3c65441c82 wp-block-paragraph\">It seems awfully high but <br \/><strong>$2.6 billion is the estimated average total capitalized R&amp;D cost<\/strong> <br \/>for the development of just 1 new drug.<sup> <a href=\"#_ftn2\">[2]<\/a>\u00a0<\/sup><\/p>\n<\/blockquote>\n\n\n\n<p class=\"wp-block-paragraph\">The economics of antibiotic development has been critically reviewed by knowledgeable and independent experts.<a href=\"#_ftn2\">[3]<\/a>&nbsp; They all make the point that curative short-term antibiotics are a poor investment financially.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">At least for now!<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">If any of this is surprising to you, you haven\u2019t been paying attention. Welcome to the world of Big Pharma and its profit-driven philosophy!&nbsp; None of this is really new; frankly, it all makes good (business) sense.&nbsp; If society dislikes the status quo, it has the power to change the playing field and make antibacterial R&amp;D more attractive similar to what we had in the 90s.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Some changes are sure to come; they will be made once a cry for change becomes louder because of an unforeseen epidemic. Once we reach that point, resistance is pointless.&nbsp; And ID folks know a lot about resistance!<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>ABBREVIATIONS<\/strong><br \/>AE        adverse event<br \/>HUS\u00a0\u00a0\u00a0\u00a0 hemolytic-uremic syndrome<br \/>FQ\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0fluoroquinolone<br \/>PK        pharmacokinetics<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>REFERENCES<\/strong><br \/><a href=\"#_ftnref1\" id=\"_ftn1\">[1]<\/a> Andriole, V. (Ed). The Quinolones.&nbsp; Academic Press, San Diego &#8211; 1988<br \/><a href=\"#_ftnref1\">[2]<\/a> Schuhmacher A.&nbsp; The significance of blockbusters in the pharmaceutical industry.&nbsp; Nature Rev Drug Discovery 22:177, 2023<br \/><a href=\"https:\/\/allphasepharma.com\/dir\/wp-admin\/post.php?post=7364&amp;action=edit#_ftnref1\">[3]<\/a> Mossiakos E. Policies and incentives for promoting innovation in antibiotic research. LSE 2010<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>This is a somewhat nostalgic retro blog.&nbsp; I was leafing through a book by Vince Andriole called \u2018The Quinolones\u2019.[1]&nbsp; First released in 1988, its third edition is from 2000.&nbsp; It provided in-depth coverage of quinolone chemistry, PK, microbiology, efficacy and safety.&nbsp; It was a great review of the large and <a class=\"more-link\" href=\"https:\/\/allphasepharma.com\/dir\/2026\/06\/20\/7364\/antibiotic-development-in-pharma-is-dead-for-now\/\">Continue reading <span class=\"screen-reader-text\">  ANTIBIOTIC DEVELOPMENT IN PHARMA IS DEAD \u2013 FOR NOW<\/span><span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":7367,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[227,3,18],"tags":[809,2689,1271,2700,403,2695,2702,220,2691,796,517,42,2690,236,2703,1002,509,795,799,216,246,1063,1583,2692,1793,2693,516,213,599,916,2696,655,2705,2704,2544,2694,2697,218,2699,1005,2701,1064,2698],"class_list":["post-7364","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-recent_literature","category-the_news","category-the_viewpoint","tag-abbott","tag-aes-of-quinolone-class","tag-allphase-pharma-consulting","tag-andriole","tag-antibiotic-blog","tag-balofloxacin","tag-bay-y3113","tag-bayer","tag-blockbuster-drugs","tag-bms","tag-cipro","tag-ciprofloxacin","tag-class-effects-of-fluoroquinolones","tag-delafloxacin","tag-enoxacin","tag-fleroxacin","tag-fluoroquinolones","tag-gatifloxacin","tag-gemifloxacin","tag-grepafloxacin","tag-gsk","tag-gyrase-inhibitor","tag-harald-reinhart","tag-hcv-therapy","tag-hemolytic-uremic-syndrome","tag-hiv-therapy","tag-levaquin","tag-levofloxacin","tag-melinta","tag-ofloxacin","tag-pazufloxacin","tag-pfizer","tag-pomalidomide","tag-pomalyst","tag-remdesivir","tag-rufloxacin","tag-sitafloxacin","tag-sparfloxacin","tag-tarvid","tag-temafloxacin","tag-the-quinolones","tag-topoisomerase-inhibitor","tag-tosufloxacin"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/06\/FQ-Slider.jpg?fit=1090%2C180&ssl=1","jetpack_shortlink":"https:\/\/wp.me\/p4KWFr-1UM","jetpack_sharing_enabled":true,"jetpack-related-posts":[{"id":269,"url":"https:\/\/allphasepharma.com\/dir\/2014\/06\/16\/269\/the-antibiotic-pipeline-how-new-is-new\/","url_meta":{"origin":7364,"position":0},"title":"The Antibiotic Pipeline: How \u201cNew\u201d is New","author":"Harald","date":"June 16, 2014","format":false,"excerpt":"In a recent \u2018Viewpoint\u2019 article, Dr. Fauci, Director of NIAID,\u00a0mentioned that \"industry has expanded the pipeline of new antibacterial drugs...with 14-agents currently in phase 3 clinical trials\".[1] Regarding the number of drugs in late development, his statement may be correct but many of these drugs are anything but new.\u00a0 Reviewing\u2026","rel":"","context":"In &quot;The Viewpoint&quot;","block_context":{"text":"The Viewpoint","link":"https:\/\/allphasepharma.com\/dir\/category\/the_viewpoint\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2014\/06\/new-3-pipelines.jpg?fit=640%2C200&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2014\/06\/new-3-pipelines.jpg?fit=640%2C200&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2014\/06\/new-3-pipelines.jpg?fit=640%2C200&ssl=1&resize=525%2C300 1.5x"},"classes":[]},{"id":637,"url":"https:\/\/allphasepharma.com\/dir\/2014\/07\/19\/637\/antibiotics-with-ocular-toxicity\/","url_meta":{"origin":7364,"position":1},"title":"Antibiotics with Ocular Toxicity","author":"Harald","date":"July 19, 2014","format":false,"excerpt":"The recent discussion whether fluoroquinolones (FQ) cause retinal detachment was short-lived and soon put to rest.\u00a0\u00a0 The issue was raised by 2 observational studies but no signal was seen in a larger and better designed\u00a0 Danish study.\u00a0 So it seems the association is probably spurious [i]. At first blush such\u2026","rel":"","context":"In &quot;The News&quot;","block_context":{"text":"The News","link":"https:\/\/allphasepharma.com\/dir\/category\/the_news\/"},"img":{"alt_text":"smiley-150838_640","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2014\/07\/smiley-150838_640.png?resize=350%2C200","width":350,"height":200},"classes":[]},{"id":1907,"url":"https:\/\/allphasepharma.com\/dir\/2015\/09\/03\/1907\/mrsa-fluoroquinolones-an-interesting-bunch-playing-a-high-stakes-game\/","url_meta":{"origin":7364,"position":2},"title":"MRSA Fluoroquinolones \u2013 An Interesting Bunch Playing a High-Stakes Game","author":"Harald","date":"September 3, 2015","format":false,"excerpt":"Fluoroquinolones (FQ) of the ofloxacin\/ciprofloxacin generation were mainly active against Gram-negative bacteria, distinguishing themselves as cidal IV\/PO drugs with high\u00a0potency\u00a0against most lactose- and non-lactose fermenters.\u00a0 They were excellent against problem pathogens like P. aeruginosa, had excellent efficacy\u00a0against Salmonellae, the Gonococcus and other Neisseriae, and you could count on them for\u2026","rel":"","context":"In &quot;The News&quot;","block_context":{"text":"The News","link":"https:\/\/allphasepharma.com\/dir\/category\/the_news\/"},"img":{"alt_text":"antiMRSA 1 copy","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/09\/antiMRSA-1-copy.jpg?resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/09\/antiMRSA-1-copy.jpg?resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/09\/antiMRSA-1-copy.jpg?resize=525%2C300 1.5x"},"classes":[]},{"id":2205,"url":"https:\/\/allphasepharma.com\/dir\/2015\/12\/23\/2205\/qidp-antibiotics-2015-year-end-update\/","url_meta":{"origin":7364,"position":3},"title":"QIDP Antibiotics  &#8211;  2015 Year-End Update","author":"Harald","date":"December 23, 2015","format":false,"excerpt":"Here an updated listing of all QIDP drugs we are aware of as of 12\/24\/2015. Today just\u00a0facts and numbers; we will provide an interpretation of the current landscape in upcoming blogs. There are\u00a058 drugs which garnered QIDP status and these are listed in the Main Table below. With the recent\u2026","rel":"","context":"In &quot;QIDP Antibiotics&quot;","block_context":{"text":"QIDP Antibiotics","link":"https:\/\/allphasepharma.com\/dir\/category\/qidp_antibiotic\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/12\/QIDP-slider.jpg?fit=640%2C200&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/12\/QIDP-slider.jpg?fit=640%2C200&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/12\/QIDP-slider.jpg?fit=640%2C200&ssl=1&resize=525%2C300 1.5x"},"classes":[]},{"id":2911,"url":"https:\/\/allphasepharma.com\/dir\/2016\/11\/25\/2911\/prospecting-antibiotics\/","url_meta":{"origin":7364,"position":4},"title":"Prospecting for New Antibiotics","author":"Harald","date":"November 25, 2016","format":false,"excerpt":"The QIDP designation was introduced in 2012 to incentivize drug development in antiinfectives. QIDP came with several attractive features, such as prolongation of patent life, FDA\u00a0expedited review and more.\u00a0 In addition, FDA made it quite easy to garner the label.\u00a0 As you can see, there is really no downside to\u2026","rel":"","context":"In &quot;Did you know...?&quot;","block_context":{"text":"Did you know...?","link":"https:\/\/allphasepharma.com\/dir\/category\/interesting_facts\/"},"img":{"alt_text":"engine-qidp-blog","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/11\/Engine-QIDP-blog.jpg?resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/11\/Engine-QIDP-blog.jpg?resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/11\/Engine-QIDP-blog.jpg?resize=525%2C300 1.5x"},"classes":[]},{"id":521,"url":"https:\/\/allphasepharma.com\/dir\/2014\/07\/06\/521\/aeromonas-salmonicida-trouble-for-aquaculture-with-drug-resistance\/","url_meta":{"origin":7364,"position":5},"title":"Aeromonas salmonicida: Trouble for Aquaculture with Drug Resistance","author":"Harald","date":"July 6, 2014","format":false,"excerpt":"Aeromonas salmonicida causes furunculosis in salmon hatcheries and in freshwater fish.\u00a0 The organism has several recognized virulence mechanisms including the T3SS\u00a0[1].\u00a0 A. salmonicida\u00a0has become resistant to penicillin, tetracycline and erythromycin.\u00a0 It remains susceptible to chloramphenicol and aminoglycoside according to a publication from Romania [2] but another reference describes it as\u2026","rel":"","context":"In &quot;Did you know...?&quot;","block_context":{"text":"Did you know...?","link":"https:\/\/allphasepharma.com\/dir\/category\/interesting_facts\/"},"img":{"alt_text":"Salmon","src":"http:\/\/allphasepharma.com\/dir\/wp-content\/uploads\/2014\/07\/Salmon.jpe","width":350,"height":200},"classes":[]}],"jetpack_likes_enabled":true,"_links":{"self":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts\/7364","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/comments?post=7364"}],"version-history":[{"count":21,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts\/7364\/revisions"}],"predecessor-version":[{"id":7397,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts\/7364\/revisions\/7397"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/media\/7367"}],"wp:attachment":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/media?parent=7364"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/categories?post=7364"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/tags?post=7364"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}